High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique

Parveen Khan, Alan T. McGown, Martin J. Dawson, Gordon Jayson, Joseph A. Prendiville, George Pettit, Derek Crowther

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

An HPLC assay incorporating a solid-phase extraction technique has been devised for bryostatin-1. Quantitation of bryostatin was found to be linear over the concentration range 0.012-25 μg/ml (0.2-25 ng on column) and was found to have a limit of detection of 0.2 ng on column, with a correlation coefficient of 0.9999. Following extraction of bryostatin over a range of concentrations from horse serum (0.012-25 μg/ml) and human serum (0.01-0.32 μg/ml) using a 100-mg C18 solid-phase extraction cartridge, extraction efficiencies consistently greater than 90% were obtained for extraction from horse serum and varied between 57 and 85% from human serum. However, on extending this work to blood samples from patients undergoing therapy with bryostatin-1, the drug was not detectable even at the maximum dose given, demonstrating the rapid loss of this agent from peripheral circulation.

Original languageEnglish (US)
Pages (from-to)113-117
Number of pages5
JournalJournal of Chromatography B: Biomedical Applications
Volume709
Issue number1
DOIs
StatePublished - May 8 1998

Keywords

  • Bryostatin-1

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint Dive into the research topics of 'High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique'. Together they form a unique fingerprint.

  • Cite this